|
[1]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and treatment of cholestasis liver diseases (2015) [J].J Clin Hepatol, 2015, 31 (12) :1989-1999. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.胆汁淤积性肝病诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1989-1999.
|
|
[2]BORTOLINI M, ALMASIO P, BRAY G, et al.Multicentre survey of the prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease[J].Drug Investigation, 1992, 4 (Suppl 4) :83-89.
|
|
[3]BEUERS U, TRAUNER M, JANSEN P, et al.New paradigms in the treatment of hepatic cholestasis:From UDCA to FXR, PXRand beyond[J].J Hepatol, 2015, 62 (1 Suppl) :s25-s37.
|
|
[4]SANTIAGO P, SCHEINBERG AR, LEVY C.Cholestatic liver diseases:New targets, new therapies[J].Therap Adv Gastroenterol, 2018, 11:1756284818787400.
|
|
[5]HARMS MH, LAMMERS WJ, THORBURN D, et al.Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis:Risk factors and time trends in incidence and outcome[J].Am J Gastroenterol, 2018, 113 (2) :254-264.
|
|
[6]KARLSEN TH, FOLSERAAS T, THORBURN D, et al.Primary sclerosing cholangitis-a comprehensive review[J].J Hepatol, 2017, 67 (6) :1298-1323.
|
|
[7]LAZARIDIS KN, LARUSSO NF.Primary sclerosing cholangitis[J].N Engl J Med, 2016, 375 (12) :1161-1170.
|
|
[8]OLSSON R, BOBERG KM, de MUCKADELL OS, et al.Highdose ursodeoxycholic acid in primary sclerosing cholangitis:A5-year multicenter, randomized, controlled study[J].Gastroenterology, 2005, 129 (5) :1464-1472.
|
|
[9]LINDOR KD, KOWDLEY KV, LUKETIC VA, et al.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J].Hepatology, 2009, 50 (3) :808-814.
|
|
[10]SHI J, LI Z, ZENG X, et al.Ursodeoxycholic acid in primary sclerosing cholangitis:Meta-analysis of randomized controlled trials[J].Hepatol Res, 2009, 39 (9) :865-873.
|
|
[11]OTHMAN MO, DUNKELBERG J, ROY PK.Urosdeoxycholic acid in primary sclerosing cholangitis:A meta-analysis and systematic review[J].Arab J Gastroenterol, 2012, 13 (3) :103-110.
|
|
[12] TRAUNER M, FUCHS CD, HALILBASIC E, et al.New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J].Hepatology, 2017, 65 (4) :1393-1404.
|
|
[13]de VRIES E, BEUERS U.Management of cholestatic disease in 2017[J].Liver Int, 2017, 37 (Suppl 1) :123-129.
|
|
[14]STEDMAN CA, LIDDLE C, COULTER SA, et al.Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury[J].Proc Natl Acad Sci U S A, 2005, 102 (6) :2063-2068.
|
|
[15]TENG S, PIQUETTE-MILLER M.Hepatoprotective role of PXRactivation and MRP3 in cholic acid-induced cholestasis[J].Br JPharmacol, 2007, 151 (3) :367-376.
|
|
[16]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:A proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.
|
|
[17]DYSON JK, HIRSCHFIELD GM, ADAMS DH, et al.Novel therapeutic targets in primary biliary cirrhosis[J].Nat Rev Gastroenterol Hepatol, 2015, 12 (3) :147-158.
|
|
[18]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[19]KOWDLEY KV, LUKETIC V, CHAPMAN R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J].Hepatology, 2018, 67 (5) :1890-1902.
|
|
[20]LARUSSO NF, BOWLUS CL, LEVY C, et al.PC.01.8 The AESOP trial:A randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis[J].Digest Liver Dis, 2018, 50 (2) :e67.
|
|
[21]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
|
|
[22]MAYO MJ, WIGG AJ, LEGGETT BA, et al.NGM282 for treatment of patients with primary biliary cholangitis:A multicenter, randomized, double-blind, placebo-controlled trial[J].Hepatol Commun, 2018, 2 (9) :1037-1050.
|
|
[23]CORPECHOT C, CHAZOUILLRES O, ROUSSEAU A, et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J].N Engl J Med, 2018, 378 (23) :2171-2181.
|
|
[24]YIN Q, LI J, XIA Y, et al.Systematic review and meta-analysis:Bezafibrate in patients with primary biliary cirrhosis[J].Drug Des Devel Ther, 2015, 9:5407-5419.
|
|
[25]JONES D, BOUDES PF, SWAIN MG, et al.Seladelpar (MBX-8025) , a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind, randomised, placebo-controlled, phase2, proof-of-concept study[J].Lancet Gastroenterol Hepatol, 2017, 2 (10) :716-726.
|
|
[26]BOUDES P, MICHAEL G, BOWLUS C, et al.Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis[J].J Hepatol, 2018, 68:s105-s364.
|
|
[27]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.
|
|
[28]MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.
|
|
[29]HOMMES DW, ERKELENS W, PONSIOEN C, et al.A doubleblind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis[J].J Clin Gastroenterol, 2008, 42 (5) :522-526.
|
DownLoad: